Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
AVEO Stock Summary
In the News
4 Drug Stocks That More Than Doubled This Year
We present four biotech stocks, AVEO, CABA, VRNA and WVE, which despite the current volatile market, have provided more than twice the returns in 2022.
Are Medical Stocks Lagging AVEO Pharmaceuticals (AVEO) This Year?
Here is how AVEO Pharmaceuticals (AVEO) and Merit Medical (MMSI) have performed compared to their sector so far this year.
AVEO Oncology (AVEO): Strong Industry, Solid Earnings Estimate Revisions
AVEO Oncology (AVEO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
What Makes AVEO Pharmaceuticals (AVEO) a Strong Momentum Stock: Buy Now?
Does AVEO Pharmaceuticals (AVEO) have what it takes to be a top stock pick for momentum investors? Let's find out.
AVEO Pharmaceuticals (AVEO) Reports Q3 Loss, Tops Revenue Estimates
AVEO (AVEO) delivered earnings and revenue surprises of 43.75% and 1.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
AVEO Pharmaceuticals (AVEO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
AVEO (AVEO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AVEO Oncology (AVEO) to Report Q3 Earnings: Is a Beat in Store?
AVEO Oncology's (AVEO) third-quarter earnings is expected to reflect strong Fotivda sales. The company is likely to beat the Zacks Consensus Estimate.
Are Medical Stocks Lagging AVEO Pharmaceuticals (AVEO) This Year?
Here is how AVEO Pharmaceuticals (AVEO) and Akero Therapeutics, Inc. (AKRO) have performed compared to their sector so far this year.
Why LG Chem Is Buying AVEO Oncology (AVEO) For $566 Million
LG Chem is buying AVEO Oncology for $566 million. These are the details.
Biopharma Stock Soaring on Buyout News
Aveo Pharmaceuticals Inc (NASDAQ:AVEO) stock is soaring today, up 40.7% at $14.74 at last glance, after news that South Korean chemical company LG Chem plans to buy the biopharmaceutical name for $15 per share, or roughly $566 million, in an all-cash deal.
AVEO Financial details
AVEO Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.72 | 0.41 | 1.87 | 0.28 | 1.82 | |
Net income per share | -6.14 | -0.41 | 0.61 | -1.66 | -2.86 | |
Operating cash flow per share | -1.81 | -1.91 | -0.19 | -1.77 | -2.68 | |
Free cash flow per share | -1.81 | -1.91 | -0.19 | -1.79 | -2.68 | |
Cash per share | 3.16 | 1.87 | 3.11 | 2.89 | 4.08 | |
Book value per share | -3.85 | -2.08 | 0.97 | 1.65 | 2.14 | |
Tangible book value per share | -3.85 | -2.08 | 0.97 | 1.65 | 2.14 | |
Share holders equity per share | -3.85 | -2.08 | 0.97 | 1.65 | 2.14 | |
Interest debt per share | 1.97 | 1.62 | 1.14 | 0.74 | -0.19 | |
Market cap | 295.54M | 209.17M | 95.99M | 123.49M | 100.38M | |
Enterprise value | 317.65M | 203.78M | 81.97M | 75.87M | 29.84M | |
P/E ratio | -4.55 | -39.25 | 10.23 | -3.47 | -1.64 | |
Price to sales ratio | 39 | 38.67 | 3.33 | 20.52 | 2.58 | |
POCF ratio | -15.42 | -8.36 | -32.89 | -3.25 | -1.75 | |
PFCF ratio | -15.42 | -8.36 | -32.89 | -3.22 | -1.75 | |
P/B Ratio | -7.25 | -7.68 | 6.47 | 3.5 | 2.19 | |
PTB ratio | -7.25 | -7.68 | 6.47 | 3.5 | 2.19 | |
EV to sales | 41.91 | 37.67 | 2.85 | 12.61 | 0.77 | |
Enterprise value over EBITDA | -5.08 | -64.94 | 7.32 | -2.23 | -0.52 | |
EV to operating cash flow | -16.58 | -8.14 | -28.08 | -2 | -0.52 | |
EV to free cash flow | -16.58 | -8.14 | -28.08 | -1.98 | -0.52 | |
Earnings yield | -0.22 | -0.03 | 0.1 | -0.29 | -0.61 | |
Free cash flow yield | -0.06 | -0.12 | -0.03 | -0.31 | -0.57 | |
Debt to equity | -0.45 | -0.7 | 1.06 | 0.4 | 0 | |
Debt to assets | 0.37 | 0.68 | 0.31 | 0.21 | 0 | |
Net debt to EBITDA | -0.35 | 1.72 | -1.25 | 1.4 | 1.23 | |
Current ratio | 1.56 | 1.54 | 2.4 | 3.87 | 5.59 | |
Interest coverage | -12.14 | -11.57 | -0.21 | -24.22 | 12.25 | |
Income quality | 0.29 | 4.7 | -0.31 | 1.07 | 1.07 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 1.21 | 1.99 | 0.39 | 3.69 | 0 | |
Research and developement to revenue | 3.32 | 3.82 | 0.62 | 3.77 | 0.68 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0.01 | 0 | |
Capex to revenue | 0 | 0 | 0 | -0.06 | 0 | |
Capex to depreciation | 0 | 0 | 0 | -17.29 | 0 | |
Stock based compensation to revenue | 0.14 | 0.47 | 0.08 | 0.39 | 0.13 | |
Graham number | 23.05 | 4.37 | 3.64 | 7.85 | 11.74 | |
ROIC | 1.29 | 3.09 | -0.01 | -0.88 | -1.24 | |
Return on tangible assets | -1.3 | -0.19 | 0.19 | -0.53 | -0.58 | |
Graham Net | -5.39 | -2.18 | 0.86 | 1.45 | 1.68 | |
Working capital | 18.06M | 9.82M | 29.48M | 48.56M | 86.01M | |
Tangible asset value | -40.76M | -27.23M | 14.85M | 35.29M | 45.87M | |
Net current asset value | -40.78M | -27.23M | 14.85M | 33.89M | 45.27M | |
Invested capital | -0.45 | -0.7 | 1.06 | 0.4 | 0 | |
Average receivables | 714.5K | 1.71M | 2.33M | 1.41M | 5.5M | |
Average payables | 2.31M | 2.97M | 2.48M | 2.42M | 3.05M | |
Average inventory | 0 | 0 | 0 | 0 | 828K | |
Days sales outstanding | 19.36 | 204.19 | 20.67 | 72.59 | 92.12 | |
Days payables outstanding | 0 | 0 | 0 | 990.92 | 208.97 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 127.6 | |
Receivables turnover | 18.85 | 1.79 | 17.65 | 5.03 | 3.96 | |
Payables turnover | 0 | 0 | 0 | 0.37 | 1.75 | |
Inventory turnover | 0 | 0 | 0 | 0 | 2.86 | |
ROE | 1.6 | 0.2 | 0.63 | -1.01 | -1.33 | |
Capex per share | 0 | 0 | 0 | -0.02 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.44 | 0.41 | 0.61 | 0.73 | 0.88 | |
Net income per share | -0.3 | -0.44 | -0.33 | -0.27 | -0.13 | |
Operating cash flow per share | -0.23 | -0.35 | -0.24 | -0.07 | 0.01 | |
Free cash flow per share | -0.23 | -0.35 | -0.24 | -0.07 | 0.01 | |
Cash per share | 2.74 | 2.54 | 2.29 | 2.24 | 2.24 | |
Book value per share | 1.49 | 1.33 | 1.07 | 0.89 | 0.83 | |
Tangible book value per share | 1.49 | 1.33 | 1.07 | 0.89 | 0.83 | |
Share holders equity per share | 1.49 | 1.33 | 1.07 | 0.89 | 0.83 | |
Interest debt per share | 1.01 | -0.2 | 1.14 | 1.15 | 1.15 | |
Market cap | 212.43M | 161.26M | 192.72M | 226.34M | 284.91M | |
Enterprise value | 177M | 90.73M | 157.07M | 194.61M | 246.19M | |
P/E ratio | -5.12 | -2.64 | -4.23 | -5.97 | -16.32 | |
Price to sales ratio | 14 | 11.34 | 9.21 | 8.94 | 9.36 | |
POCF ratio | -26.32 | -13.24 | -23.45 | -92.31 | 1.47K | |
PFCF ratio | -26.32 | -13.24 | -23.45 | -92.31 | 1.47K | |
P/B Ratio | 4.15 | 3.52 | 5.22 | 7.4 | 9.88 | |
PTB ratio | 4.15 | 3.52 | 5.22 | 7.4 | 9.88 | |
EV to sales | 11.67 | 6.38 | 7.51 | 7.69 | 8.09 | |
Enterprise value over EBITDA | -19.25 | -6.39 | -17.46 | -27.27 | -114.45 | |
EV to operating cash flow | -21.93 | -7.45 | -19.11 | -79.37 | 1.27K | |
EV to free cash flow | -21.93 | -7.45 | -19.11 | -79.37 | 1.27K | |
Earnings yield | -0.05 | -0.09 | -0.06 | -0.04 | -0.02 | |
Free cash flow yield | -0.04 | -0.08 | -0.04 | -0.01 | 0 | |
Debt to equity | 0.65 | 0 | 1.03 | 1.26 | 1.34 | |
Debt to assets | 0.31 | 0 | 0.39 | 0.39 | 0.38 | |
Net debt to EBITDA | 3.85 | 4.97 | 3.96 | 4.45 | 18 | |
Current ratio | 4.83 | 5.59 | 4.81 | 3.1 | 2.37 | |
Interest coverage | -7.99 | 0.89 | -7.59 | -6.14 | -1.97 | |
Income quality | 0.78 | 1.68 | 0.81 | 0.29 | -0.06 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.49 | 0.43 | 0.49 | 0.49 | 0.36 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0.09 | 0.1 | 0.06 | 0.06 | 0.05 | |
Graham number | 3.18 | 3.65 | 2.82 | 2.34 | 1.54 | |
ROIC | -0.11 | -0.28 | -0.13 | -0.12 | -0.04 | |
Return on tangible assets | -0.1 | -0.15 | -0.12 | -0.1 | -0.04 | |
Graham Net | 1.28 | 1.05 | 0.84 | 0.65 | 0.59 | |
Working capital | 85.6M | 86.01M | 77.42M | 66.09M | 58.31M | |
Tangible asset value | 51.23M | 45.87M | 36.94M | 30.59M | 28.85M | |
Net current asset value | 50.12M | 45.27M | 36.45M | 30.06M | 28.34M | |
Invested capital | 0.65 | 0 | 1.03 | 1.26 | 1.34 | |
Average receivables | 7.55M | 9.66M | 11.79M | 14.95M | 17.95M | |
Average payables | 4.04M | 3.82M | 2.86M | 3.31M | 4.32M | |
Average inventory | 626K | 1.45M | 1.68M | 1.51M | 1.21M | |
Days sales outstanding | 56.4 | 62.07 | 59.26 | 57.37 | 58.42 | |
Days payables outstanding | 254.16 | 120.06 | 111.45 | 105.86 | 114.41 | |
Days of inventory on hand | 64.61 | 73.31 | 62.64 | 38.76 | 25.11 | |
Receivables turnover | 1.6 | 1.45 | 1.52 | 1.57 | 1.54 | |
Payables turnover | 0.35 | 0.75 | 0.81 | 0.85 | 0.79 | |
Inventory turnover | 1.39 | 1.23 | 1.44 | 2.32 | 3.58 | |
ROE | -0.2 | -0.33 | -0.31 | -0.31 | -0.15 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
AVEO Frequently Asked Questions
What is AVEO Pharmaceuticals, Inc. stock symbol ?
AVEO Pharmaceuticals, Inc. is a US stock , located in Boston of Ma and trading under the symbol AVEO
Is AVEO Pharmaceuticals, Inc. buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $14. The lowest prediction is $14 and the highest is $14
What is AVEO stock prediction ?
What is AVEO Pharmaceuticals, Inc. stock quote today ?
AVEO Pharmaceuticals, Inc. stock price is $15 today.
Is AVEO Pharmaceuticals, Inc. stock public?
Yes, AVEO Pharmaceuticals, Inc. is a publicly traded company.